Voyageur Pharmaceuticals Ltd
VM.CA
$0.04
Closing
0.00
1D
▼-26.67%
YTD
Market cap
$5.59M
52 week high
$0.07
52 week low
$0.03
Volume
5,225
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$5.59M
Analysts' Rating
-
Price Target (Mean)
-
Total Analysts
0
P/E
Operating Margin
0.00%
Beta
0.51
Revenue Growth (Annual)
-
52 week high
$0.07
52 week low
$0.03
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Voyageur Pharmaceuticals Ltd. is a Canada-based company that designs carbon-neutral pharmaceutical manufacturing plants with a carbon credit de-carbonization strategy for customers. The Company is focused on the development of barium, iodine and carbon active pharmaceutical ingredients (API) and high-performance imaging contrast agents for the medical imaging marketplace. The Company owns a 100% interest in three barium sulfate (barite) projects, including the Frances Creek property, suitable in grade for the pharmaceutical marketplace, with additional interests in a high-grade iodine, lithium & bromine brine project located in Utah, United States of America. The Company’s product pipeline includes SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101, and VY-103.
